Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma

Clinical Trial ID NCT01403285

Rank	Title	Journal	Year	PubWeight™‹?›
1	Trial watch: Chemotherapy with immunogenic cell death inducers.	Oncoimmunology	2012	1.33
2	Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.	Oncoimmunology	2012	1.30
3	Trial watch: Peptide vaccines in cancer therapy.	Oncoimmunology	2012	1.17
4	Immunotherapy advances for glioblastoma.	Neuro Oncol	2014	1.07
5	Current vaccine trials in glioblastoma: a review.	J Immunol Res	2014	0.96
6	Antigen-specific vaccines for cancer treatment.	Hum Vaccin Immunother	2014	0.89
7	Immune-checkpoint blockade and active immunotherapy for glioma.	Cancers (Basel)	2013	0.88
8	Unique biology of gliomas: challenges and opportunities.	Trends Neurosci	2012	0.87
9	Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy.	Oncoimmunology	2015	0.85
10	Tenascin-C: Exploitation and collateral damage in cancer management.	Cell Adh Migr	2015	0.85
11	The value of EGFRvIII as the target for glioma vaccines.	Am Soc Clin Oncol Educ Book	2014	0.75
12	Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses.	Neurosurgery	2014	0.75
13	Current Studies of Immunotherapy on Glioblastoma.	J Neurol Neurosurg	2014	0.75
14	Vaccine therapies in malignant glioma.	Curr Neurol Neurosci Rep	2015	0.75